Aroflo

Aroflo

salmeterol + fluticasone

Manufacturer:

Aristopharma

Distributor:

KTZ
Concise Prescribing Info
Contents
Per 25 mcg/125 mcg inhaler Salmeterol xinafoate 25 mcg, fluticasone propionate 125 mcg. Per 25 mcg/250 mcg inhaler Salmeterol xinafoate 25 mcg, fluticasone propionate 250 mcg
Indications/Uses
Regular treatment of asthma in patients not adequately controlled w/ inhaled corticosteroids & 'as needed' inhaled short-acting β2-agonist; in patients already adequately controlled on both inhaled corticosteroids & long-acting β2-agonist.
Dosage/Direction for Use
Adult & adolescent ≥12 yr 2 puffs bd.
Contraindications
Special Precautions
Should not be used to treat acute asthma. Avoid abrupt discontinuation. Patients w/ pulmonary TB, severe CV disorders, heart rhythm abnormalities, DM, thyrotoxicosis, uncorrected hypokalemia & predisposed to low levels of serum K. Pregnancy & lactation.
Adverse Reactions
Tremor, palpitations, headache; cardiac arrythmia, hypersensitivity reactions eg, rash, oedema, angioedema; oropharyngeal irritation; hoarseness, candidiasis; adrenal suppression, growth retardation, decreased bone mineral density.
Drug Interactions
Nonselective & selective β-blockers. CYP3A4 inhibitors (eg, ketoconazole, ritonavir).
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AK06 - salmeterol and fluticasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Aroflo inhaler 125 mcg/25 mcg
Packing/Price
120 puff x 1's
Form
Aroflo inhaler 250 mcg/25 mcg
Packing/Price
120 puff x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in